by The global anti-inflammatory therapeutics market size was valued at US$ 99.6 billion in 2021 and is anticipated to grow US$ 127.5 billion by 2030, registering a compound annual growth rate (CAGR) of 4.5% from 2022 to 2030.
The anti-inflammatory therapeutics market report covering various industry elements and growth trends helpful for predicting the market’s future.
The study provides a strong base for the anti-inflammatory therapeutics market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2030.
This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2022 to 2030. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the anti-inflammatory therapeutics report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the anti-inflammatory therapeutics market have been studied and analysed across many developments.
Report Scope of the Anti-Inflammatory Therapeutics Market
| Report Coverage | Details |
| Market Size in 2022 | USD 102.37 Billion |
| Market Size by 2030 | USD 127.5 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 4.5% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Class, Indication, Application, Distribution Channel, and Geography |
Research Approach
The comprehensive report on the global anti-inflammatory therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global anti-inflammatory therapeutics market.
It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
Key Players are Eli Lily and Company, AstraZeneca PLC, Amgen Inc., F. Hoffman, Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, Pfizer, Inc., La Roche AG, Ferring Pharmaceuticals, Bioventus, Zimmer Biomet Holdings, Inc., Flexion Therapeutics, Inc
Market Segmentations
By Drug Class
- Anti-inflammatory Biologics
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
By Indication
- Arthritis
- Rheumatoid Arthritis
- Osteoarthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Gout
- Respiratory diseases
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Multiple sclerosis
- Psoriasis
- Inflammatory bowel disease
- Crohn’s Disease
- Ulcerative Colitis
- Other inflammatory diseases
By Application
- Autoimmune
- Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
- Respiratory Diseases
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Anti-Inflammatory Therapeutics Market
5.1. COVID-19 Landscape: Anti-Inflammatory Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Anti-Inflammatory Therapeutics Market, By Drug Class
8.1. Anti-Inflammatory Therapeutics Market, by Drug Class, 2022-2030
8.1.1. Anti-inflammatory Biologics
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Corticosteroids
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Anti-Inflammatory Therapeutics Market, By Indication
9.1. Anti-Inflammatory Therapeutics Market, by Indication, 2022-2030
9.1.1. Arthritis
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Respiratory diseases
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Multiple sclerosis
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Psoriasis
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Inflammatory bowel disease
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Other inflammatory diseases
9.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Anti-Inflammatory Therapeutics Market, By Application
10.1. Anti-Inflammatory Therapeutics Market, by Application, 2022-2030
10.1.1. Autoimmune
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Respiratory Diseases
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Anti-Inflammatory Therapeutics Market, By Distribution Channel
11.1. Anti-Inflammatory Therapeutics Market, by Distribution Channel, 2022-2030
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Anti-Inflammatory Therapeutics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Eli Lily and Company
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AstraZeneca PLC
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Amgen Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffman
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Abbvie, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Johnson & Johnson
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck & CO., Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global anti-inflammatory therapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for anti-inflammatory therapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2229
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
